Menveo (meningococcal-groups A, C, W-135 and Y oligosaccharide CRM197 conjugate vaccine) / GSK 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 


12345»
  • ||||||||||  MenQuadfi (meningococcal A C Y and W polysaccharide tetanus toxoid conjugate vaccine) / Sanofi, Menveo (meningococcal-groups A, C, W-135 and Y oligosaccharide CRM197 conjugate vaccine) / GSK, Typhim Vi (typhoid polysaccharide vaccine) / Sanofi
    Journal, IO biomarker:  Monophosphoryl Lipid A-based Adjuvant to Promote the Immunogenicity of Multivalent Meningococcal Polysaccharide Conjugate Vaccines. (Pubmed Central) -  Apr 20, 2024   
    Many Gram-negative bacterial polysaccharide vaccines, including the tetravalent meningococcal conjugate vaccines (MCV4) and typhoid Vi polysaccharide vaccines, do not incorporate adjuvants...Consistent with this hypothesis, two Food and Drug Administration-approved MCV4 vaccines, MENVEO and MenQuadfi, lack TLR4 ligands...Turbo upregulated the expression of the costimulatory molecules CD40 and CD86 on B cells, and Turbo-driven adjuvanticity is lost in mice deficient in CD40 and CD86. These data suggest that Turbo induces the required costimulatory molecules for its adjuvant activity and that incorporation of Turbo could make bacterial polysaccharide vaccines more immunogenic, minimize booster requirements, and be cost-effective, particularly for those individuals in low- and middle-income and disease-endemic countries.
  • ||||||||||  Penbraya (PF-06886992) / Pfizer
    Journal:  Penbraya: A pentavalent meningococcal vaccine. (Pubmed Central) -  Mar 15, 2024   
    These data suggest that Turbo induces the required costimulatory molecules for its adjuvant activity and that incorporation of Turbo could make bacterial polysaccharide vaccines more immunogenic, minimize booster requirements, and be cost-effective, particularly for those individuals in low- and middle-income and disease-endemic countries. No abstract available
  • ||||||||||  Vaxzevria (ChAdOx1-S recombinant) / University of Oxford, Emergent Biosolutions, Jenner Institute, Vaccitech, AstraZeneca
    Trial completion date, Trial primary completion date:  Investigating a Vaccine Against COVID-19 (clinicaltrials.gov) -  Aug 1, 2023   
    P2/3,  N=12390, Active, not recruiting, 
    MenACYW-TT may provide an alternative to the standard-of-care for meningococcal disease prevention in those aged???12 months. Trial completion date: Mar 2023 --> Mar 2024 | Trial primary completion date: Mar 2023 --> Mar 2024
  • ||||||||||  MenQuadfi (meningococcal A C Y and W polysaccharide tetanus toxoid conjugate vaccine) / Sanofi
    Enrollment open:  Study of Immunogenicity and Safety of MenQuadfi (clinicaltrials.gov) -  Jul 12, 2023   
    P4,  N=180, Recruiting, 
    Trial completion date: Mar 2023 --> Mar 2024 | Trial primary completion date: Mar 2023 --> Mar 2024 Not yet recruiting --> Recruiting
  • ||||||||||  MenQuadfi (meningococcal A C Y and W polysaccharide tetanus toxoid conjugate vaccine) / Sanofi
    New P4 trial:  Study of Immunogenicity and Safety of MenQuadfi (clinicaltrials.gov) -  Jul 3, 2023   
    P4,  N=180, Not yet recruiting, 
  • ||||||||||  Menveo (meningococcal-groups A, C, W-135 and Y oligosaccharide CRM197 conjugate vaccine) / GSK
    Journal:  Development of a New Solid-Phase Extraction Base Method for Free Saccharide Content Estimation of Meningococcal Conjugate Vaccines. (Pubmed Central) -  Nov 18, 2022   
    GlaxoSmithKline (GSK) is currently developing a fully liquid presentation to ease the administration of the licensed quadrivalent conjugate vaccine (Menveo) against meningococcal serogroup A, C, W, and Y (MenACWY) infections...Mathematical models have been used to support technical knowledge in reducing the need for experimental development. This results in an improved, faster, and platform-based technique for FS separation with one single pretreatment applicable to all antigens of the multivalent meningococcal vaccine.
  • ||||||||||  Menveo (meningococcal-groups A, C, W-135 and Y oligosaccharide CRM197 conjugate vaccine) / GSK, Menactra (Meningococcal-groups A, C, Y and W-135 polysaccharide diphtheria toxoid conjugate vaccine) / Sanofi
    Vaccine Schedule Disparities Exist for Pediatric Patients with Sickle Cell Disease (ENMCC - Hall D) -  Nov 4, 2022 - Abstract #ASH2022ASH_3134;    
    We found that patients with SCD were more likely to receive vaccines according to the general population vaccine schedule rather than the SCD-specific vaccine schedule. In addition, reliance on pediatricians to provide PPSV23 for satellite clinic patients resulted in lower PPSV23 vaccination rates among these patients.
  • ||||||||||  Menveo (meningococcal-groups A, C, W-135 and Y oligosaccharide CRM197 conjugate vaccine) / GSK, Bexsero (meningococcal group B vaccine) / GSK
    Trial completion:  MenABCWY  (clinicaltrials.gov) -  Oct 24, 2022   
    P3,  N=3670, Completed, 
    In addition, reliance on pediatricians to provide PPSV23 for satellite clinic patients resulted in lower PPSV23 vaccination rates among these patients. Active, not recruiting --> Completed
  • ||||||||||  Menveo (meningococcal-groups A, C, W-135 and Y oligosaccharide CRM197 conjugate vaccine) / GSK, Bexsero (meningococcal group B vaccine) / GSK, MenABCWY vaccine (GSK3536819A) / GSK
    Review, Journal:  Public health perspective of a pentavalent meningococcal vaccine combining antigens of MenACWY-CRM and 4CMenB. (Pubmed Central) -  Oct 19, 2022   
    Recruiting --> Active, not recruiting A pentavalent MenABCWY has the potential to provide further public health benefits through practical, broad IMD protection programmes encompassing serogroups A, B, C, W and Y, and is currently in late-stage development.
  • ||||||||||  Journal:  Adult immunization. (Pubmed Central) -  Oct 14, 2022   
    Not yet recruiting --> Recruiting No abstract available
  • ||||||||||  Review, Journal:  Vaccination prophylaxis for recurrent invasive meningococcal diseases (Pubmed Central) -  Aug 3, 2022   
    The risk of becoming infected again with a different or the same serotype is significantly increased after an infection has gone through and in the case of certain previous illnesses such as complement defects.The Committee for Infectious Diseases and Vaccinations of the German Academy for Pediatrics and Adolescent Health proposes the following approach for prevention of recurrent invasive meningococcal infections:Children and adolescents without a complete meningococcal vaccination status should be vaccinated with 4CMenB (Bexero®, Trumenba®) and/or vaccinated against serogroups A, C, W and Y (Menveo®, Nimenrix®, MenQuadfi®) immediately after healing of an invasive meningococcal disease according to the specification of the information for healthcare professionals. Prior isolated screening for complement deficiencies is not necessary for the vaccination decision in these patients.
  • ||||||||||  Menveo (meningococcal-groups A, C, W-135 and Y oligosaccharide CRM197 conjugate vaccine) / GSK, Cervarix (recombinant human papillomavirus bivalent vaccine) / GSK, Japan Vaccine, Gardasil 9 (human papillomavirus 9-valent vaccine, recombinant) / Merck (MSD)
    Trial completion date, Trial primary completion date:  The KEN SHE Study on HPV-vaccine Efficacy (clinicaltrials.gov) -  Aug 1, 2022   
    P4,  N=2275, Active, not recruiting, 
    Prior isolated screening for complement deficiencies is not necessary for the vaccination decision in these patients. Trial completion date: Nov 2022 --> Feb 2024 | Trial primary completion date: Nov 2022 --> Feb 2024
  • ||||||||||  Menveo (meningococcal-groups A, C, W-135 and Y oligosaccharide CRM197 conjugate vaccine) / GSK, Typhim Vi (typhoid polysaccharide vaccine) / Sanofi, Typbar TCV (typhoid Vi conjugate vaccine) / Bharat Biotech
    Trial completion, Trial completion date:  VAST: Vaccines Against Salmonella Typhi (clinicaltrials.gov) -  Jul 5, 2022   
    P2b,  N=112, Completed, 
    Trial primary completion date: Dec 2022 --> Nov 2023 Unknown status --> Completed | Trial completion date: Dec 2018 --> Jun 2022
  • ||||||||||  Menveo (meningococcal-groups A, C, W-135 and Y oligosaccharide CRM197 conjugate vaccine) / GSK, Bexsero (meningococcal group B vaccine) / GSK
    Trial completion:  A Sourcing Study to Collect Human Blood Samples From Healthy Adults (clinicaltrials.gov) -  Jun 27, 2022   
    P4,  N=1021, Completed, 
    Unknown status --> Completed | Trial completion date: Dec 2018 --> Jun 2022 Active, not recruiting --> Completed
  • ||||||||||  Menveo (meningococcal-groups A, C, W-135 and Y oligosaccharide CRM197 conjugate vaccine) / GSK
    Journal:  Clinically proven specification setting for a meningococcal serogroup a conjugate vaccine. (Pubmed Central) -  May 20, 2022   
    GSK is currently working to improve the commercial presentation of the licensed quadrivalent conjugate vaccine (Menveo) for use against meningococcal serogroup A, C, W, Y (MenACWY) infections...The clinical material was then exposed to a temperature of 22.5 ± 2.5 °C for 59 days to generate FS OAc content of about 35% and 40%, respectively, which was then delivered to the patients in the clinical trial. To the best of our knowledge, this work represents the first example in the field of vaccine research where statistical models have been used to rationally design tailored lots, with the goal of setting EoSL and release specification limits based on data collected on artificially aged clinical material, in which the FS and OAc levels tested were intended to support a product shelf-life of at least 24 months.
  • ||||||||||  GSK4001785A / GSK
    Trial completion date, Trial primary completion date:  A Study on the Safety and Immune Responses to the GVGH altSonflex1-2-3 Vaccine Against Shigellosis in Adults, Children, and Infants (clinicaltrials.gov) -  Apr 25, 2022   
    P1/2,  N=550, Recruiting, 
    Since the introduction of combined quadrivalent vaccines, there has been a positive impact demonstrated over time on public health regarding IMD, with a decline in the incidence of combined IMD serogroups and an increase in immunisation rates. Trial completion date: Apr 2024 --> Jul 2024 | Trial primary completion date: Apr 2024 --> Jul 2024
  • ||||||||||  Menveo (meningococcal-groups A, C, W-135 and Y oligosaccharide CRM197 conjugate vaccine) / GSK, Menactra (Meningococcal-groups A, C, Y and W-135 polysaccharide diphtheria toxoid conjugate vaccine) / Sanofi, Nimenrix (MenACWY-TT) / Pfizer
    Trial completion:  Adolescent MenACWY Booster Study (clinicaltrials.gov) -  Mar 11, 2022   
    P4,  N=244, Completed, 
    Recruiting --> Completed Active, not recruiting --> Completed
  • ||||||||||  Menveo (meningococcal-groups A, C, W-135 and Y oligosaccharide CRM197 conjugate vaccine) / GSK
    Journal:  Molecular modeling provides insights into the loading of sialic acid-containing antigens onto CRM: the role of chain flexibility in conjugation efficiency and glycoconjugate architecture. (Pubmed Central) -  Feb 25, 2022   
    The tetravalent Menveo® conjugate vaccine is well-defined: a simple monomeric structure of oligosaccharides terminally conjugated to amino groups of the carrier protein CRM...Our simulations reveal a correlation between Nm antigen flexibility (NmW > NmC > NmY) and the number of chains attached to CRM, suggesting that increased flexibility enables accommodation of additional chains on the protein surface. Further, in silico models of the glycoconjugates confirm the relatively large hydrodynamic size of the saccharide chains and indicate steric constraints to further conjugation.